CN106890310A - 一种治疗痰浊型心血管类疾病的中药组方及其制备方法 - Google Patents
一种治疗痰浊型心血管类疾病的中药组方及其制备方法 Download PDFInfo
- Publication number
- CN106890310A CN106890310A CN201710018807.1A CN201710018807A CN106890310A CN 106890310 A CN106890310 A CN 106890310A CN 201710018807 A CN201710018807 A CN 201710018807A CN 106890310 A CN106890310 A CN 106890310A
- Authority
- CN
- China
- Prior art keywords
- weight portions
- weight
- weight portion
- blood
- portions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010062717 Increased upper airway secretion Diseases 0.000 title claims abstract description 49
- 208000026435 phlegm Diseases 0.000 title claims abstract description 49
- 208000024172 Cardiovascular disease Diseases 0.000 title claims abstract description 31
- 208000011580 syndromic disease Diseases 0.000 title claims abstract description 18
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 239000008280 blood Substances 0.000 claims abstract description 101
- 210000004369 blood Anatomy 0.000 claims abstract description 97
- 239000003814 drug Substances 0.000 claims abstract description 50
- 244000269722 Thea sinensis Species 0.000 claims abstract description 40
- 239000000843 powder Substances 0.000 claims abstract description 31
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims abstract description 30
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims abstract description 30
- 235000009685 Crataegus X maligna Nutrition 0.000 claims abstract description 30
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims abstract description 30
- 235000009486 Crataegus bullatus Nutrition 0.000 claims abstract description 30
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims abstract description 30
- 235000009682 Crataegus limnophila Nutrition 0.000 claims abstract description 30
- 235000004423 Crataegus monogyna Nutrition 0.000 claims abstract description 30
- 235000002313 Crataegus paludosa Nutrition 0.000 claims abstract description 30
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims abstract description 30
- 241000219784 Sophora Species 0.000 claims abstract description 27
- 235000006468 Thea sinensis Nutrition 0.000 claims abstract description 27
- 235000020279 black tea Nutrition 0.000 claims abstract description 27
- 241000304531 Allium macrostemon Species 0.000 claims abstract description 26
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 18
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 18
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims abstract description 6
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229940116269 uric acid Drugs 0.000 claims abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 37
- 210000002216 heart Anatomy 0.000 claims description 20
- 235000013616 tea Nutrition 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 12
- 239000000463 material Substances 0.000 claims description 10
- 241000233866 Fungi Species 0.000 claims description 8
- 241000287828 Gallus gallus Species 0.000 claims description 8
- 244000194101 Ginkgo biloba Species 0.000 claims description 8
- 241000408747 Lepomis gibbosus Species 0.000 claims description 8
- 244000197580 Poria cocos Species 0.000 claims description 8
- 235000008599 Poria cocos Nutrition 0.000 claims description 8
- 239000012141 concentrate Substances 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 8
- 210000004317 gizzard Anatomy 0.000 claims description 8
- 239000012528 membrane Substances 0.000 claims description 8
- 235000020236 pumpkin seed Nutrition 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims description 6
- 235000008331 Pinus X rigitaeda Nutrition 0.000 claims description 6
- 235000011613 Pinus brutia Nutrition 0.000 claims description 6
- 241000018646 Pinus brutia Species 0.000 claims description 6
- 244000234609 Portulaca oleracea Species 0.000 claims description 6
- 235000001855 Portulaca oleracea Nutrition 0.000 claims description 6
- 244000223082 Syzygium paniculatum Species 0.000 claims description 6
- 235000016641 Syzygium paniculatum Nutrition 0.000 claims description 6
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims description 6
- 235000013399 edible fruits Nutrition 0.000 claims description 6
- 210000000582 semen Anatomy 0.000 claims description 6
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 claims description 5
- 235000009508 confectionery Nutrition 0.000 claims description 5
- 230000002829 reductive effect Effects 0.000 claims description 5
- 238000005119 centrifugation Methods 0.000 claims description 4
- 230000006837 decompression Effects 0.000 claims description 4
- 239000000706 filtrate Substances 0.000 claims description 4
- 239000002994 raw material Substances 0.000 claims description 4
- 238000011084 recovery Methods 0.000 claims description 4
- 238000007654 immersion Methods 0.000 claims description 3
- 230000035508 accumulation Effects 0.000 claims description 2
- 238000009825 accumulation Methods 0.000 claims description 2
- 230000001093 anti-cancer Effects 0.000 claims description 2
- 241001092040 Crataegus Species 0.000 claims 7
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 claims 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 claims 1
- 238000000605 extraction Methods 0.000 claims 1
- 238000010992 reflux Methods 0.000 claims 1
- 238000001291 vacuum drying Methods 0.000 claims 1
- 240000000171 Crataegus monogyna Species 0.000 abstract description 23
- 230000002526 effect on cardiovascular system Effects 0.000 abstract description 7
- 206010028980 Neoplasm Diseases 0.000 abstract description 6
- 230000002792 vascular Effects 0.000 abstract description 6
- 201000011510 cancer Diseases 0.000 abstract description 4
- 230000001269 cardiogenic effect Effects 0.000 abstract description 4
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 abstract description 3
- 238000004140 cleaning Methods 0.000 abstract description 3
- 206010022437 insomnia Diseases 0.000 abstract description 3
- 210000003516 pericardium Anatomy 0.000 abstract description 3
- 230000000694 effects Effects 0.000 description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 21
- 201000010099 disease Diseases 0.000 description 19
- 229940079593 drug Drugs 0.000 description 16
- 230000017531 blood circulation Effects 0.000 description 14
- 238000000034 method Methods 0.000 description 12
- 230000001737 promoting effect Effects 0.000 description 12
- 230000003213 activating effect Effects 0.000 description 11
- 210000001367 artery Anatomy 0.000 description 11
- 230000004087 circulation Effects 0.000 description 11
- 206010002383 Angina Pectoris Diseases 0.000 description 10
- 208000002193 Pain Diseases 0.000 description 10
- 210000003462 vein Anatomy 0.000 description 10
- 210000004204 blood vessel Anatomy 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 9
- 239000007789 gas Substances 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000007812 deficiency Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 208000032843 Hemorrhage Diseases 0.000 description 5
- 208000031226 Hyperlipidaemia Diseases 0.000 description 5
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 5
- 208000029078 coronary artery disease Diseases 0.000 description 5
- 230000002708 enhancing effect Effects 0.000 description 5
- 229930003944 flavone Natural products 0.000 description 5
- 150000002212 flavone derivatives Chemical class 0.000 description 5
- 235000011949 flavones Nutrition 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 230000007170 pathology Effects 0.000 description 5
- 229920001282 polysaccharide Polymers 0.000 description 5
- 239000005017 polysaccharide Substances 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 230000035900 sweating Effects 0.000 description 5
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 5
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 4
- 208000000059 Dyspnea Diseases 0.000 description 4
- 206010013975 Dyspnoeas Diseases 0.000 description 4
- ZVXBAHLOGZCFTP-UHFFFAOYSA-N Efloxate Chemical compound C=1C(OCC(=O)OCC)=CC=C(C(C=2)=O)C=1OC=2C1=CC=CC=C1 ZVXBAHLOGZCFTP-UHFFFAOYSA-N 0.000 description 4
- 108010088842 Fibrinolysin Proteins 0.000 description 4
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 description 4
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 229960003859 efloxate Drugs 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 4
- 229940001501 fibrinolysin Drugs 0.000 description 4
- 230000023597 hemostasis Effects 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 4
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 4
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 4
- 235000005493 rutin Nutrition 0.000 description 4
- 229960004555 rutoside Drugs 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 3
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 241000361919 Metaphire sieboldi Species 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 229960000711 alprostadil Drugs 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 210000001772 blood platelet Anatomy 0.000 description 3
- 230000001914 calming effect Effects 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000005714 functional activity Effects 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 230000002107 myocardial effect Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- -1 polysaccharide compound Chemical class 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 244000000383 Allium odorum Species 0.000 description 2
- 235000018645 Allium odorum Nutrition 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 2
- 235000017491 Bambusa tulda Nutrition 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 244000082204 Phyllostachys viridis Species 0.000 description 2
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 2
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 2
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 2
- NTFQHAKUNDRGJR-UHFFFAOYSA-N Sophoradiol Natural products CC1(C)CC(O)C2(C)CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1 NTFQHAKUNDRGJR-UHFFFAOYSA-N 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 206010002022 amyloidosis Diseases 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 239000011425 bamboo Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000000496 cardiotonic agent Substances 0.000 description 2
- 235000005487 catechin Nutrition 0.000 description 2
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 229950001002 cianidanol Drugs 0.000 description 2
- 230000001112 coagulating effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000003527 fibrinolytic agent Substances 0.000 description 2
- 230000003480 fibrinolytic effect Effects 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 230000004907 flux Effects 0.000 description 2
- 210000004392 genitalia Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 239000000413 hydrolysate Substances 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000000302 ischemic effect Effects 0.000 description 2
- 239000010977 jade Substances 0.000 description 2
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 235000005875 quercetin Nutrition 0.000 description 2
- 229960001285 quercetin Drugs 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 230000036299 sexual function Effects 0.000 description 2
- ZEGUWBQDYDXBNS-FVFJQADASA-N sophoradiol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)[C@H](O)CC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C ZEGUWBQDYDXBNS-FVFJQADASA-N 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 206010042772 syncope Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229940026510 theanine Drugs 0.000 description 2
- 230000002537 thrombolytic effect Effects 0.000 description 2
- 230000001732 thrombotic effect Effects 0.000 description 2
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 239000011800 void material Substances 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 244000235603 Acacia catechu Species 0.000 description 1
- 241000173529 Aconitum napellus Species 0.000 description 1
- 108010059616 Activins Proteins 0.000 description 1
- 102000005606 Activins Human genes 0.000 description 1
- 244000295724 Allium chinense Species 0.000 description 1
- 235000016790 Allium chinense Nutrition 0.000 description 1
- 206010002368 Anger Diseases 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- 206010002953 Aphonia Diseases 0.000 description 1
- 235000006226 Areca catechu Nutrition 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 206010007191 Capillary fragility Diseases 0.000 description 1
- 206010007556 Cardiac failure acute Diseases 0.000 description 1
- 241000522254 Cassia Species 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 101710095468 Cyclase Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241001465251 Ephedra sinica Species 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 102100033053 Glutathione peroxidase 3 Human genes 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 101000871067 Homo sapiens Glutathione peroxidase 3 Proteins 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- IPMYMEWFZKHGAX-UHFFFAOYSA-N Isotheaflavin Natural products OC1CC2=C(O)C=C(O)C=C2OC1C(C1=C2)=CC(O)=C(O)C1=C(O)C(=O)C=C2C1C(O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-UHFFFAOYSA-N 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 101150040663 PGI1 gene Proteins 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010034568 Peripheral coldness Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- IKGXIBQEEMLURG-UHFFFAOYSA-N Rutin Chemical compound OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-UHFFFAOYSA-N 0.000 description 1
- 241000593989 Scardinius erythrophthalmus Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 206010042170 Strangury Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- UXRMWRBWCAGDQB-UHFFFAOYSA-N Theaflavin Natural products C1=CC(C2C(CC3=C(O)C=C(O)C=C3O2)O)=C(O)C(=O)C2=C1C(C1OC3=CC(O)=CC(O)=C3CC1O)=CC(O)=C2O UXRMWRBWCAGDQB-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 108091006088 activator proteins Proteins 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000488 activin Substances 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000019804 backache Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 206010007625 cardiogenic shock Diseases 0.000 description 1
- 230000035568 catharsis Effects 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019225 fermented tea Nutrition 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 235000020717 hawthorn extract Nutrition 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 235000008777 kaempferol Nutrition 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 210000000088 lip Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 108010070324 lumbrokinase Proteins 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000000282 nail Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000018338 positive regulation of fibrinolysis Effects 0.000 description 1
- 229940127293 prostanoid Drugs 0.000 description 1
- 150000003814 prostanoids Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 230000000862 serotonergic effect Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000014620 theaflavin Nutrition 0.000 description 1
- IPMYMEWFZKHGAX-ZKSIBHASSA-N theaflavin Chemical compound C1=C2C([C@H]3OC4=CC(O)=CC(O)=C4C[C@H]3O)=CC(O)=C(O)C2=C(O)C(=O)C=C1[C@@H]1[C@H](O)CC2=C(O)C=C(O)C=C2O1 IPMYMEWFZKHGAX-ZKSIBHASSA-N 0.000 description 1
- 229940026509 theaflavin Drugs 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 210000000216 zygoma Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/06—Treating tea before extraction; Preparations produced thereby
- A23F3/14—Tea preparations, e.g. using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/38—Sucrose-free products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/44—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/48—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing plants or parts thereof, e.g. fruits, seeds, extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/736—Prunus, e.g. plum, cherry, peach, apricot or almond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G2200/00—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF containing organic compounds, e.g. synthetic flavouring agents
- A23G2200/06—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF containing organic compounds, e.g. synthetic flavouring agents containing beet sugar or cane sugar if specifically mentioned or containing other carbohydrates, e.g. starches, gums, alcohol sugar, polysaccharides, dextrin or containing high or low amount of carbohydrate
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G2200/00—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF containing organic compounds, e.g. synthetic flavouring agents
- A23G2200/10—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF containing organic compounds, e.g. synthetic flavouring agents containing amino-acids, proteins, e.g. gelatine, peptides, polypeptides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G2200/00—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF containing organic compounds, e.g. synthetic flavouring agents
- A23G2200/14—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF containing organic compounds, e.g. synthetic flavouring agents containing fruits, nuts, e.g. almonds, seeds, plants, plant extracts or essential oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种治疗痰浊型心血管类疾病的中药组方及其制备方法,所述中药组方由山楂2‑4重量份、地龙蛋白2‑4重量份、薤白2‑4重量份、黑茶粉2‑4重量份、槐花2‑4重量份和玉竹2‑4重量份组成。该中药能降低血尿酸,清理心血管垃圾;解决心源性失眠;解决心包筋膜组织肿痛,软化硬化血管;增强癌症患者的抵抗力。
Description
技术领域:
本发明属于中药领域,涉及一种治疗心血管类疾病的中药组方及其制备方法,尤其是一种治疗痰浊型心血管类疾病的中药组方及其制备方法。
背景技术:
心血管疾病,又称为循环系统疾病,是一系列涉及循环系统的疾病,循环系统指人体内运送血液的器官和组织,可以细分为急性和慢性,一般都是与动脉硬化有关。其表现为胸闷如窒,呼吸欠畅,重者有胸痛,严重者心痛彻背,背痛彻心,兼有汗出。阴虚火旺型除上述表现外,伴见五心烦热,或午后潮热,两颧色红,口渴,大便秘结,舌红少苔,脉细数。心血管疾病的病种很多,常见的有冠心病、高血压、心胶痛、心疾梗死等。临床上,西医治疗主要有扩张血管剂、降压药和抗血小板凝聚剂等药物,这些药副作用较大,长期使用会对血管和人体器官带来不同程度的伤害。近年来,中医药防治心血管病研究获得多方面进展,如活血化瘀治疗冠心病心绞痛、益气活血或益气养阴活血治疗急性心肌梗塞或心功能不全、益气通脉温阳治疗缓慢性心律失常、益气养阳透毒治疗病毒性心肌炎、理气活血预防冠心病介入性治疗后再狭窄等,皆显示有肯定效果。
在心脑血管疾病的治疗药物中,中西药的应用各有侧重,中药以其副作用小的优势也占据较大的市场份额。临床上常用于治疗心脑血管疾病的药物有银杏叶制剂、复方丹参滴丸等。
胸痹以胸部闷痛为主症的一类心血管类疾病,患者多见膻中或心前区憋闷疼痛,甚则痛彻左肩背、咽喉、胃脘部、左上臂内侧等部位,呈反复发作性,一般持续几秒到几十分钟,休息或用药后可缓解。常伴有心悸、气短、自汗,甚则喘息不得卧,严重者可见疼痛剧烈,持续不解,汗出肢冷,面色苍白,唇甲青紫,脉散乱或微细欲绝等危候,可发生猝死。真心痛乃胸痹的进一步发展,症见心痛剧烈,甚则持续不解,伴有汗出、肢冷、面白、唇紫、手足青紫,脉微或结代等危重证候。真心痛是胸痹进一步发展的严重病证,其特点为剧烈而持久的胸骨后疼痛,伴心悸、水肿、肢冷、喘促、汗出、面色苍白等症状,甚至危及生命。《灵枢·厥病》:“真心痛,手足清至节,心痛甚,旦发夕死,夕发旦死。”,《诸病源候论·心病诸候》:“心为诸脏主而藏神,其正经不可伤,伤之而痛为真心痛。”《医碥·心痛》:“真心痛,其证卒然大痛,咬牙噤口,气冷,汗出不休,面黑,手足青过节,冷如冰,旦发夕死,夕发旦死,不治。不忍坐视,用猪心煎取汤,入麻黄、肉桂、干姜、附子服之,以散其寒,或可死中求生。”其证心痛恰在心窝之中,伴手足冰冷,面目青红(见《辨证录·心痛门》)。本虚是发病基础,发病条件是标实。如寒凝气滞、血瘀痰浊,闭塞心脉,心脉不通,出现心胸疼痛(心绞痛),严重者部分心脉突然闭塞,气血运行中断,可见心胸猝然大痛,而发为真心痛(心肌梗死)。若心气不足,运血无力,心脉瘀阻,心血亏虚,气血运行无力,可见心动悸,脉结代;若心肾阳虚,水邪泛滥,水饮凌心射肺,可出现心悸、水肿、喘促(心力衰竭),或亡阳厥脱、亡阴厥脱(心源性休克),或阴阳俱脱,最后导致阴阳离决。总之本病病位在心,其本在肾,总的病机为本虚标实,而在急性期则以标实为主。
现在中药治疗心血管类疾病,都是采用活血化瘀药物使经脉舒通血活瘀化;即用温热的药物配合活血化瘀药物,以温经通络散寒化瘀,驱散阴寒凝滞之邪,使经脉舒通血活瘀化。取“寒者热之”,“血得温则行”之义。寒为阴邪,最能收引经脉,凝滞气血而导致气血瘀滞。这里的寒凝包括两个方面,一是外寒客络,阳气受困;一是脾肾阳虚,阴寒内生。在临床应用散寒活血化瘀治则时,应当分清温经通阳活血通脉和补阳益火活血化瘀之法。主要有散寒化瘀药,即用温热的药物配合活血化瘀药物,以温经通络散寒化瘀,驱散阴寒凝滞之邪,使经脉舒通血活瘀化。取“寒者热之”,“血得温则行”之义。寒为阴邪,最能收引经脉,凝滞气血而导致气血瘀滞。这里的寒凝包括两个方面,一是外寒客络,阳气受困;一是脾肾阳虚,阴寒内生。在临床应用散寒活血化瘀治则时,应当分清温经通阳活血通脉和补阳益火活血化瘀之法。祛湿化瘀药,即用燥湿或渗湿的药物配合活血化瘀药物,以祛除湿邪,促使血活瘀化。湿为阴邪,其性黏滞,易阻气机而致脉络阻滞而血瘀。湿邪有外侵或内生之分,病理过程中又有寒化和热化之别;且与脾之运化,肾之温煦有密切的关系。从四肢血管性疾病的特性来看,外湿多从热化,所以具体应用祛湿活血化瘀时,又要区分清热利湿,健脾温肾利湿活血化瘀。清热化瘀药,即用寒凉的药物配合活血化瘀药物,清解热邪,以使络宁血活瘀化。是“热者寒之”之义。“夫脉者,血之府也”,所以热邪侵入脉络多及血分;又有热之甚即为毒,热邪灼津伤阴,虚热内生。“血受热则煎熬成块”,阻滞脉道,而成血瘀,由此可见,具体应用清热活血化瘀法时,首先应分清虚实,和在气在血。从而推演出清热凉血,清热解毒和养阴清热活血化瘀三法。理气化瘀药,即用理气的药物,调畅气机,气行则血行,使血活瘀化。气之为患,不外乎气滞、气虚、气逆三个方面。而四肢血管病症又以气滞、气虚多见。气为血帅,是血液运行的动力,所以气机不畅,郁滞不行则血行为之涩,而致血瘀,气虚不能推动血液运行,血行缓慢而成瘀。反之,血为气母,气赖血载,血瘀既成又致气滞,在病理上互为因果,相互影响,气血密切相关,决定了理气法在血管病症中的重要性和普遍性。又由于肝主疏泄,调畅气机,又主藏血,所以舒肝行气在四肢血管病症的治疗中更有重要的意义。综上所述,临床上具体应用时还须分辨行气和益气活血化瘀二法的应用。补血滋阴化瘀药,即用补血滋阴药物配合活血化瘀药物,以增加血液使其充盈脉道,血活瘀化。血液在脉道中流行,血量充沛则脉道充盈;血液虚少,阴津不足则脉道萎闭,继而成瘀。所以应补血滋阴,增液盈脉,活血化瘀。平肝潜阳化瘀药,即用平肝潜阳药物配合活血化瘀药物,以使阳潜血和,络通血活,而得到瘀化之目的。肝阳升发太过血随气逆,并走于上,脉络壅塞,可致血瘀。故应平肝潜阳,解除壅阻,以化血瘀。
经过多年的临床研究发现,采用活血化瘀药物使经脉舒通血活瘀化的方法治疗心血管类疾病,只能是针对一部分瘀血重的病人,有瘀血的病人必定有痰浊,有痰浊不一定发展到血瘀,所以现实临床中大部分心血管类疾病产生的根本在于人体内的痰浊,痰浊阻塞心窍,心窍为人之根本,大部分心血管类疾病的根本原因在于心窍阻塞;痰浊,痰湿系秽浊之邪,故称;是中医学的特有概念。现代医学研究发现,痰浊和高血脂、冠心病、癌症等都有关系。任何生命活动中不正常主化反应的代谢产物、合成的物质都可能与中医的痰浊有关。另外,细胞的自然衰老,也可使细胞功能减退,而逐步形成痰浊。总之,痰作为一种病理产物,又可视为一种致病因素,可无孔不入地渗透到机体的各个脏腑,经络。血液在流动过程中,其特性的不稳定、成分的变化,影响其速度、流向、方式、程度和性质的改变,可能与“津液不循常道便成痰浊”有关。血小板的聚集性、粘附性和释放功能呈病理性改变时,就必然影响血液的正常流态;红细胞压积过高,聚集性增强,变形能力低下,造成血粘度增加,使血液运行失常。由于血粘度增加,微循环亦发生障碍,甚至出现微血栓,这是痰浊在血液流变中形成的结果。实际上无论是高脂血症中的哪一型,一则直接增加血浆粘度,使脂质沉于血管壁上而生成痰浊;二则可直接作用于血管中的轴流成分,导致微小血栓的形成,而致痰瘀互结。淀粉样蛋白的来源是降解后的免疫球蛋白(Ig),当这种代谢产物在组织中沉着时,病理学上会出现一些嗜伊红性的玻璃样元定形的细胞外物质,称为淀粉样变性。从其形成原因、存在状态和临床表现看,淀粉样变性颇似中医“痰”或“痰湿”证。血脂(即血浆脂质)本是人体正常生命物质之一,当血脂浓度超过高限时便称为高脂血症。高脂血症实际可视为痰证,而血浆脂质即是“微观之痰”。综上所述,痰浊的本质,总体说来是指那些在人体生理过程或病理变化过程中,应当排出体外,而未排出,从而在体内堆积起来的代谢产物或病理产物。本发明提供了一种清除人体痰浊的药物组合,该药物能有效清理人体内产生的痰浊,从根本上实现了预防及治疗心血管类疾病。
发明内容:
本发明的目的在于克服上述现有技术的缺点,提供一种治疗痰浊型心血管类疾病的中药组方及其制备方法,该中药无毒无副作用,能治疗痰浊造成的心血管类疾病;能降低血尿酸,清理心血管垃圾;能解决心源性失眠;解决心包筋膜组织肿痛,软化硬化血管;增强癌症患者的抵抗力。
一种治疗痰浊型心血管类疾病的中药组方,所述中药组方由山楂2-4重量份、地龙蛋白2-4重量份、薤白2-4重量份、黑茶粉2-4重量份、槐花2-4重量份和玉竹2-4重量份组成。
所述山楂2.5-3.5重量份;所述地龙蛋白2.5-3.5重量份;所述薤白2.5-3.5重量份;所述黑茶粉2.5-3.5重量份;所述槐花2.5-3.5重量份;所述玉竹2.5-3.5重量份。
一种消积化痰通络利心的中药组方,所述中药组方由山楂2-4重量份、地龙蛋白2-4重量份、薤白2-4重量份、黑茶粉2-4重量份、槐花2-4重量份、玉竹2-4重量份、茯苓1-2重量份、白果1-2重量份、鸡内金1-2重量份、黑木耳1-2重量份、南瓜子1-2重量份组成。
一种抗癌降血尿酸的中药组方,所述中药组方由山楂2-4重量份、地龙蛋白2-4重量份、薤白2-4重量份、黑茶粉2-4重量份、槐花2-4重量份、玉竹2-4重量份、茯苓1-2重量份、白果1-2重量份、鸡内金1-2重量份、黑木耳1-2重量份、南瓜子1-2重量份、松籽1重量份、毛茶1重量份、黑芝麻1重量份、香菇1重量份、马齿苋1重量份、槐花1重量份、郁李仁1重量份和L-阿拉伯糖1重量份组成。
一种防治痰浊类心血管病的压片糖果,所述压片糖果的原料为:由山楂2-4重量份、地龙蛋白2-4重量份、薤白2-4重量份、黑茶粉2-4重量份、槐花2-4重量份、玉竹2-4重量份、茯苓1-2重量份、白果1-2重量份、鸡内金1-2重量份、黑木耳1-2重量份、南瓜子1-2重量份、松籽1重量份、毛茶1重量份、黑芝麻1重量份、香菇1重量份、马齿苋1重量份、槐花1重量份、郁李仁1重量份和L-阿拉伯糖1重量份组成。
一种防治痰浊类心血管病的茶粉,所述茶粉的原料为:由山楂2-4重量份、地龙蛋白2-4重量份、薤白2-4重量份、黑茶粉2-4重量份、槐花2-4重量份、玉竹2-4重量份、茯苓1-2重量份、白果1-2重量份、鸡内金1-2重量份、黑木耳1-2重量份、南瓜子1-2重量份、松籽1重量份、毛茶1重量份、黑芝麻1重量份、香菇1重量份、马齿苋1重量份、槐花1重量份、郁李仁1重量份和L-阿拉伯糖1重量份组成。
一种治疗痰浊型心血管类疾病的中药制备方法,按照如下步骤:
第一步:称取山楂2-4重量份、地龙蛋白2-4重量份、薤白2-4重量份、槐花2-4重量份和玉竹2-4重量份,投入药用粉碎机中,粉碎至80-100目;
第二步:加药材质量10-12倍量的乙醇,乙醇的体积浓度为80-90%,分2次回流提取,每次回流2-3小时,合并提取液,过滤,滤液减压浓缩回收乙醇,得醇提浓缩液;
第三步:在第二步的药渣中加入黑茶粉2-4重量份,加药材重量10-20倍量的水,浸泡0.5-1小时,煎煮3次,每次1小时,煎煮温度为100摄氏度;
第四步:合并三次水煎液,过滤后搅拌均匀、放置36-48小时后离心,离心速度为4800-5000转/分,回收离心液,与第二步中醇提浓缩液合并,减压浓缩后在70-80摄氏度条件下进行真空干燥后制成中药干粉;
第五步:将中药干粉进行真空包装,备用。
山楂抗心肌缺血,山楂对急性实验性心肌缺血具有保护作用。山楂黄酮、水解产物增加缺血心肌营养性血流量,其中以山楂水解产物作用最强。山楂在增加冠状动脉血流量的同时,还能降低心肌耗氧量,提高氧利用率。山楂黄酮具有改善动物的缺血心电图作用。山楂黄酮能缩小兔实验性心肌梗死范围。强心山楂具有增强心肌收缩力、增加心排血量的作用。山楂提取物对在体、离体蟾蜍心脏能增强心肌收缩力,作用维持时间长。目前明确的有效成分为3’,4’,5,7一四羟基黄酮一7一葡萄糖苷和芦丁。降压山楂黄酮、三萜酸静脉、腹腔及十二指肠给药,均显示有一定的降压作用,其作用机制主要与扩张外周血管作用有关。抗氧化山楂及山楂黄酮具抗氧化作用,能显著降低血清和肝脏中丙二醛(MDA)含量,增强红细胞和肝脏超氧化物歧化酶(SOD)的活性,同时增强血浆谷胱甘肽过氧化物酶(GSH—Px)活性。
地龙蛋白中有胶原酶、纤溶酶、蚓激酶、纤溶激活蛋白、核酸、微量元素等多种成分,其分子量在5000-10000,属于短链小分子物质,能顺畅的进入微血管,溶解微血管内的微栓,让硬化的微血管恢复弹性,从而解除微血管的堵塞、扭曲变形情况。其中,纤溶酶和蚓激酶能直接溶解形成人体血栓的主体物质纤维蛋白,从而发挥强力的直接溶栓作用;纤溶激活蛋白则是激活人体中的tPA,再由自身产生纤溶酶原,进而转化为人体的纤溶酶,由于这种方式是由人自己产生纤溶酶,这样间接溶解血栓,就大幅提高了其安全性。它能溶解新鲜及陈旧性血栓,提高人体自身的抗凝功能,能激活血管内皮细胞的分化特性,打通经脉、促进微血管再生,建立侧枝循环,为病灶区的心脑组织开辟新的血液通路,修复坏死的脑神经细胞,治愈偏瘫,从而达到持续溶栓的效果,对心脑血管病的预防,中风后遗症的康复意义重大。同时又有助于消除与微循环障碍有关的衰老和肿瘤发生,改善全身多种生理机能和健康状况,提高免疫力。
薤白通阳散结,行气导滞。用于胸痹心痛,脘腹痞满胀痛,泻痢后重。《本草求真》:薤,味辛则散,散则能使在上寒滞立消;味苦则降,降则能使在下寒滞立下;气温则散,散则能使在中寒滞立除;体滑则通,通则能使久痼寒滞立解。是以下痢可除,瘀血可散,喘急可止,水肿可敷,胸痹刺痛可愈,胎产可治,汤火及中恶卒死可救,实通气、滑窍、助阳佳品也。功用有类于韭,但韭则入血行气及补肾阳,此则专通寒滞及兼滑窍之为异耳。离体兔心灌流实验结果表明薤白能使冠脉流量减少(但差异无显著性),然后出现心缩力的迅速衰减,有难于恢复的特点,因此该冠脉流量减少似非由心缩力抑制所致,而可能系药物直接作用冠脉使之收缩的结果;但实验结果不完全一致,在16次实验中,作用不明显或反而使冠脉流量增加者有7次。此外,薤白对心率有抑制作用,但程度不大(小于10%)。家兔喂薤白醇提取物3周以后血中PGE1含量明显升高,这可能是醇提取物中MATS对此类前列腺素合成的增强作用。PGE1能使血小板腺苷酸环化酶活性增强,增加cAMP内源水平,能抑制血小板合成TXA2,抑制血小板聚集,有良好的防治血栓性血管疾病的功效,证明薤白醇提取物抑制实验性动脉粥样斑块形成作用强于PGE1。这可以认为薤白醇提物能抑制实验性TXA2和增加PGI1合成。这种抗血栓机制的结合,证实了薤白醇提物是一种防治血栓性心血管疾病的良药。
黑茶具有良好的降解脂肪、抗血凝、促纤维蛋白原溶解作用和显著抑制血小板聚集,还能使血管壁松弛,增加血管有效直径,从而抑制主动脉及冠状动脉内壁粥样硬化斑块的形成。达到降压、软化血管,防治心血管疾病的目的。黑茶中不仅含有丰富的抗氧化物质如儿茶素类、茶色素、黄酮类、维生素C、维生素E、D一胡萝卜素等,而且含有大量的具抗氧化作用的微量元素如锌、锰、铜(SOD的构成元素)和硒(GSHPX的构成元素)等。黑茶中的儿茶素、茶黄素、茶氨酸和茶多糖,尤其是含量较多的复杂类黄酮等都具有清除自由基的功能,因而具有抗氧化、延缓细胞衰老的作用。湖南农业大学采用现代药物筛选的尖端技术高通量筛选技术对黑茶进行肿瘤细胞模型SGC7901的高通量筛选研究,证明黑茶对肿瘤细胞具有明显的抑制作用。茶叶中特有的氨基酸茶氨酸能通过活化多巴胺能神经元,起到抑制血压升高的作用。此处,还发现茶叶中的咖啡碱和儿茶素类能使血管壁松弛,增加血管的有效直径,通过血管舒张而使血压下降。中国楼福庆等发现茶色素具有显著的抗凝、促进纤溶、防止血小板黏附聚集,抑制动脉平滑肌细胞增生的作用,还能显著降低高脂动物血清中甘油三酯、低密度脂蛋白,提高血清中高密度脂蛋白,并对ACE酶具有显著抑制作用,具有降压效果。黑茶中的茶多糖复合物是降血尿酸的主要成分。茶多糖复合物通常称为茶多糖,是一类组成成分复杂且变化较大的混合物黑茶。黑茶的茶多糖含量最高,且其组分活性也比其它茶类要强,这是因为在发酵茶中,由于糖苷酶、蛋白酶、水解酶的作用,而形成了相对长度较短的糖链和肽链的缘故,短肽链较长肽链更易被吸收,且生物活性更强。
槐花其味苦、性微寒,归肝、大肠经;入血敛降,体轻微散;具有凉血止血,清肝泻火的功效;主治肠风便血,痔血,血痢,尿血,血淋,崩漏,吐血,衄血,肝火头痛,目赤肿痛,喉痹,失音,痈疽疮疡。而从西医的角度看,槐花含芦丁(即芸香苷,Rytub)、槲皮素(Quercetin)、鞣质、槐花二醇(sophoradiol)、维生素A等物质(具体可参见下面的含量表)。芦丁能改善毛细血管的功能,保持毛细血管正常的抵抗力,防止因毛细血管脆性过大,渗透性过高引起的出血、高血压、糖尿病,服之可预防出血。
玉竹具养阴、润燥、清热、生津、止咳等功效。用作滋补药品,主治热病伤阴、虚热燥咳、心脏病、糖尿病、结核病等症。
本发明的有益效果在于:降低血尿酸,清理心血管垃圾;营养心血管同时清理心血管垃圾,从而治疗各种痰浊型心血管疾病;壮阳,强心后提高心欲,性功能,解决心源性性功能下降。痰浊阻滞心血管引起心欲下降,阻塞性器官末梢血管引起性功能下降;全面提升身体素质,长寿秘诀。心血管中痰浊容易形成血管梗塞或溢血,危害老年健康的主要威胁;安眠,解决心源性失眠;痰浊阻塞心窍,无法安睡;解决心包筋膜组织肿痛,软化硬化血管;增强癌症患者的抵抗力。
具体实施方式:
下面本发明做进一步详细描述:
实施例一:一种治疗痰浊型心血管类疾病的中药组方,所述中药组方由山楂2重量份、地龙蛋白2重量份、薤白2重量份、黑茶粉2重量份、槐花2.5重量份和玉竹2重量份组成。
一种治疗痰浊型心血管类疾病的中药制备方法,按照如下步骤:
第一步:称取山楂2重量份、地龙蛋白2重量份、薤白2重量份、槐花2.5重量份和玉竹2重量份,投入药用粉碎机中,粉碎至80-100目;
第二步:加药材质量10-12倍量的乙醇,乙醇的体积浓度为80-90%,分2次回流提取,每次回流2-3小时,合并提取液,过滤,滤液减压浓缩回收乙醇,得醇提浓缩液;
第三步:在第二步的药渣中加入黑茶粉2重量份,加药材重量10-20倍量的水,浸泡0.5-1小时,煎煮3次,每次1小时,煎煮温度为100摄氏度;
第四步:合并三次水煎液,过滤后搅拌均匀、放置36-48小时后离心,离心速度为4800-5000转/分,回收离心液,与第二步中醇提浓缩液合并,减压浓缩后在70-80摄氏度条件下进行真空干燥后制成中药干粉;
第五步:将中药干粉进行真空包装,备用。
实施例二:一种治疗痰浊型心血管类疾病的中药组方,所述中药组方由山楂3重量份、地龙蛋白4重量份、薤白2重量份、黑茶粉2重量份、槐花2.5重量份和玉竹3重量份组成。
一种治疗痰浊型心血管类疾病的中药制备方法,按照如下步骤:
第一步:称取山楂3重量份、地龙蛋白4重量份、薤白2重量份、槐花2.5重量份和玉竹3重量份,投入药用粉碎机中,粉碎至80-100目;
第二步:加药材质量10-12倍量的乙醇,乙醇的体积浓度为80-90%,分2次回流提取,每次回流2-3小时,合并提取液,过滤,滤液减压浓缩回收乙醇,得醇提浓缩液;
第三步:在第二步的药渣中加入黑茶粉2重量份,加药材重量10-20倍量的水,浸泡0.5-1小时,煎煮3次,每次1小时,煎煮温度为100摄氏度;
第四步:合并三次水煎液,过滤后搅拌均匀、放置36-48小时后离心,离心速度为4800-5000转/分,回收离心液,与第二步中醇提浓缩液合并,减压浓缩后在70-80摄氏度条件下进行真空干燥后制成中药干粉;
第五步:将中药干粉进行真空包装,备用。
本文中所选择对象主要系高血压、冠心病人中有高脂血症,且排除由于肝、肾、胆道疾病所致血脂增高者,给予心而平片治疗。自2015年10月开始至2016年12月非西安病人治疗75例(简称外地组),自2015年10月开始至2016年12月在西安治疗75例(简称西安组),共治疗150例。两组的性别、年龄、职业及健康情况见表1。
表1---140例高脂血症病人情况
以上所述,仅是本发明的较佳实施例而已,并非对本发明作任何形式上的限制,虽然本发明已以较佳实施例揭露如上,然而并非用以限定本发明,任何熟悉本专业的技术人员,在不脱离本发明技术方案范围内,当可利用上述揭示的方法及技术内容作出些许的更动或修饰为等同变化的等效实施例,但凡是未脱离本发明技术方案的内容,依据本发明的技术实质对以上实施例所作的任何简单修改、等同变化与修饰,仍属于本发明技术方案的范围内。
Claims (7)
1.一种治疗痰浊型心血管类疾病的中药组方,其特征在于:所述中药组方由山楂2-4重量份、地龙蛋白2-4重量份、薤白2-4重量份、黑茶粉2-4重量份、槐花2-4重量份和玉竹2-4重量份组成。
2.如权利要求1所述治疗痰浊型心血管类疾病的中药组方,其特征在于:所述山楂2.5-3.5重量份;所述地龙蛋白2.5-3.5重量份;所述薤白2.5-3.5重量份;所述黑茶粉2.5-3.5重量份;所述槐花2.5-3.5重量份;所述玉竹2.5-3.5重量份。
3.一种消积化痰通络利心的中药组方,所述中药组方由山楂2-4重量份、地龙蛋白2-4重量份、薤白2-4重量份、黑茶粉2-4重量份、槐花2-4重量份、玉竹2-4重量份、茯苓1-2重量份、白果1-2重量份、鸡内金1-2重量份、黑木耳1-2重量份、南瓜子1-2重量份组成。
4.一种抗癌降血尿酸的中药组方,所述中药组方由山楂2-4重量份、地龙蛋白2-4重量份、薤白2-4重量份、黑茶粉2-4重量份、槐花2-4重量份、玉竹2-4重量份、茯苓1-2重量份、白果1-2重量份、鸡内金1-2重量份、黑木耳1-2重量份、南瓜子1-2重量份、松籽1重量份、毛茶1重量份、黑芝麻1重量份、香菇1重量份、马齿苋1重量份、槐花1重量份、郁李仁1重量份和L-阿拉伯糖1重量份组成。
5.一种防治痰浊类心血管病的压片糖果,所述压片糖果的原料为:由山楂2-4重量份、地龙蛋白2-4重量份、薤白2-4重量份、黑茶粉2-4重量份、槐花2-4重量份、玉竹2-4重量份、茯苓1-2重量份、白果1-2重量份、鸡内金1-2重量份、黑木耳1-2重量份、南瓜子1-2重量份、松籽1重量份、毛茶1重量份、黑芝麻1重量份、香菇1重量份、马齿苋1重量份、槐花1重量份、郁李仁1重量份和L-阿拉伯糖1重量份组成。
6.一种防治痰浊类心血管病的茶粉,所述茶粉的原料为:由山楂2-4重量份、地龙蛋白2-4重量份、薤白2-4重量份、黑茶粉2-4重量份、槐花2-4重量份、玉竹2-4重量份、茯苓1-2重量份、白果1-2重量份、鸡内金1-2重量份、黑木耳1-2重量份、南瓜子1-2重量份、松籽1重量份、毛茶1重量份、黑芝麻1重量份、香菇1重量份、马齿苋1重量份、槐花1重量份、郁李仁1重量份和L-阿拉伯糖1重量份组成。
7.一种治疗痰浊型心血管类疾病的中药制备方法,其特征在于,按照如下步骤:
第一步:称取山楂2-4重量份、地龙蛋白2-4重量份、薤白2-4重量份、槐花2-4重量份和玉竹2-4重量份,投入药用粉碎机中,粉碎至80-100目;
第二步:加药材质量10-12倍量的乙醇,乙醇的体积浓度为80-90%,分2次回流提取,每次回流2-3小时,合并提取液,过滤,滤液减压浓缩回收乙醇,得醇提浓缩液;
第三步:在第二步的药渣中加入黑茶粉2-4重量份,加药材重量10-20倍量的水,浸泡0.5-1小时,煎煮3次,每次1小时,煎煮温度为100摄氏度;
第四步:合并三次水煎液,过滤后搅拌均匀、放置36-48小时后离心,离心速度为4800-5000转/分,回收离心液,与第二步中醇提浓缩液合并,减压浓缩后在70-80摄氏度条件下进行真空干燥后制成中药干粉;
第五步:将中药干粉进行真空包装,备用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710018807.1A CN106890310A (zh) | 2017-01-11 | 2017-01-11 | 一种治疗痰浊型心血管类疾病的中药组方及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710018807.1A CN106890310A (zh) | 2017-01-11 | 2017-01-11 | 一种治疗痰浊型心血管类疾病的中药组方及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106890310A true CN106890310A (zh) | 2017-06-27 |
Family
ID=59198811
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710018807.1A Pending CN106890310A (zh) | 2017-01-11 | 2017-01-11 | 一种治疗痰浊型心血管类疾病的中药组方及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106890310A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108402268A (zh) * | 2018-03-17 | 2018-08-17 | 新疆中农坤源生物科技有限公司 | 果茶压片糖果 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1095952A (zh) * | 1993-06-04 | 1994-12-07 | 陈顺志 | 一种新型药茶的生产方法 |
CN104855979A (zh) * | 2015-04-22 | 2015-08-26 | 劲膳美生物科技股份有限公司 | 降血脂非全营养配方食品 |
-
2017
- 2017-01-11 CN CN201710018807.1A patent/CN106890310A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1095952A (zh) * | 1993-06-04 | 1994-12-07 | 陈顺志 | 一种新型药茶的生产方法 |
CN104855979A (zh) * | 2015-04-22 | 2015-08-26 | 劲膳美生物科技股份有限公司 | 降血脂非全营养配方食品 |
Non-Patent Citations (1)
Title |
---|
刘铭忠等: "《中华茶道》", 31 July 2011, 长春:吉林出版集团有限责任公司 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108402268A (zh) * | 2018-03-17 | 2018-08-17 | 新疆中农坤源生物科技有限公司 | 果茶压片糖果 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101317615B (zh) | 一种银棘茶饮料及其制备方法 | |
CN103405668B (zh) | 一种治疗心律失常的药剂 | |
CN107929420A (zh) | 改善人体气血功能和提高免疫力的中药组合物和检测方法 | |
CN102205107B (zh) | 一种治疗十二指肠溃疡的中药制剂及其制备方法 | |
CN104904964A (zh) | 一种降糖降脂的罗布麻叶保健茶及其制备方法 | |
CN103202879B (zh) | 一种治疗慢性心力衰竭的中药组合物及制备方法 | |
CN104758806A (zh) | 一种治疗冠心病的煎膏剂及其制备方法 | |
CN103830616B (zh) | 治疗猪瘟的中药及其制备方法 | |
CN102526676B (zh) | 治疗慢性心力衰竭的中药、制备方法及给药方式 | |
CN105028995A (zh) | 一种配合狗粮及其制备方法 | |
CN108066712A (zh) | 一种补气养血中药组合物 | |
CN106890310A (zh) | 一种治疗痰浊型心血管类疾病的中药组方及其制备方法 | |
CN104435487A (zh) | 一种治疗高血压合并糖尿病眼底病的中药及其制备方法 | |
CN103798472B (zh) | 一种保健茶及保健养生制剂 | |
CN105435190A (zh) | 用于治疗寒热错杂型哮病的中药组合物及其制备方法 | |
CN104352717A (zh) | 一种治疗脾气虚弱型便血的中药制剂及其制备方法 | |
CN103860948A (zh) | 用于治疗气滞热壅证急性乳腺炎的中药及其制备方法 | |
KR102632013B1 (ko) | 생약재 추출물을 유효성분으로 하는 우울증 개선용 조성물 제조방법 | |
KR101543760B1 (ko) | 중풍 및 혈전 치료, 예방용 약재 조성물 | |
KR101261888B1 (ko) | 천연약재를 이용한 기능성 건강식품 제조방법 및 기능성 건강식품 | |
CN107519429B (zh) | 具有改善脾胃和促进通便排毒功能的中药组合物及制法 | |
KR20030047627A (ko) | 산수유(Comi Fructus)를 주제로한 건강식품 | |
CN105106651A (zh) | 一种治疗清气不升型神经性耳聋的中药及制备方法 | |
CN104906375B (zh) | 一种用于治疗气不摄血型紫癜的中药组合物 | |
CN104082671B (zh) | 一种改善心脑血管疾病的养生粥及其制作方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20190215 Address after: Room A1-2712, Jinye Age, 32 Zhangbajie Banjinye Road, Xi'an High-tech Zone, Shaanxi Province, 710077 Applicant after: Liuwei Science and Technology Co. Ltd., Xi'an Address before: 710068 West Side of the 6th Floor of Area 15, Business Development Park A, 69 Jinye Road, Xi'an High-tech Zone, Shaanxi Province Applicant before: Xi'an Guan Tong pharmaceutical research and Development Co Ltd |
|
TA01 | Transfer of patent application right | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170627 |
|
RJ01 | Rejection of invention patent application after publication |